LEADER 05246nam 22006375 450 001 9910879580503321 005 20240809130225.0 010 $a3-031-59815-6 024 7 $a10.1007/978-3-031-59815-9 035 $a(CKB)33812270200041 035 $a(MiAaPQ)EBC31596397 035 $a(Au-PeEL)EBL31596397 035 $a(DE-He213)978-3-031-59815-9 035 $a(EXLCZ)9933812270200041 100 $a20240809d2024 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCytokine Storm Syndrome /$fedited by Randy Q. Cron, Edward M. Behrens 205 $a2nd ed. 2024. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2024. 215 $a1 online resource (609 pages) 225 1 $aAdvances in Experimental Medicine and Biology,$x2214-8019 ;$v1448 311 1 $a3-031-59814-8 320 $aIncludes bibliographical references and index. 327 $a1. Cytokines in cytokine storm syndromes -- 2. History of HLH -- 3. The history of macrophage activation syndrome in autoimmune diseases -- 4. Clinical features of cytokine storm syndromes -- 5. Laboratory features and pathology of cytokine storm syndromes -- 6. Criteria for cytokine storm syndromes -- 7. Familial HLH genetics -- 8. Secondary HLH genetics -- 9. Genetics of macrophage activation syndrome in systemic juvenile idiopathic arthritis -- 10. CD8+ T cell biology in cytokine storm syndromes -- 11. Immunology of cytokine storm syndromes: Natural killer cells -- 12. Myeloid cells in the immunopathogenesis of cytokine storm syndrome -- 13. Cytokine storm -- 14. Primary immunodeficiencies -- 15. Infectious triggers of cytokine storm syndromes: Herpes virus family (non-EBV) -- 16. CSS associated with Epstein Barr Virus -- 17. Hemorrhagic Fever and other viruses -- 18. Cytokine storm syndrome as a manifestation of primary HIV infection -- 19. Bacteria-associated cytokine storm syndrome -- 20. Zoonoticbacterial infections triggering cytokine storm syndrome -- 21. Parasitic and fungal triggers -- 22. COVID-19 pneumonia and cytokine storm syndrome -- 23. Cytokine storm associated with Systemic Juvenile Idiopathic Arthritis -- 24. Systemic lupus erythematosus -- 25. Kawasaki disease -- 26. The intersections of autoinflammation and cytokine storm -- 27. Other rheumatic triggers -- 28. Multisystem Inflammatory Syndrome in children -- 29. Hemophagocytic lymphohistiocytosis in the context of hematological malignancies and solid tumors -- 30. Cytokine storm and sepsis-induced Multiple Organ Dysfunction Syndrome -- 31. The cytokine storm of Multicentric Castleman Disease -- 32. Cytokine storm syndromes associated with pregnancy and therapeutics -- 33. fHLH models -- 34. sHLH models -- 35. Etoposide therapy of CSS -- 36. IL-1 family blockade -- 37. IL-6 blockade -- 38. IFNy blockade -- 39. JAK inhibitors -- 40. Other immunomodulatory HLH treatments -- 41. Salvage therapy for HLH. 330 $aCytokine Storm Syndromes, including HLH and MAS, are frequently fatal disorders, particularly if not recognized early and treated during presentation. The genetics of Cytokine Storm Syndromes are being defined with many of the risk alleles giving rise to mutations in the perforin-mediated cytolytic pathway used by CD8 cytotoxic T cells and natural killer cells. These are being studied using murine models. Up to 10% of the general population may carry risk alleles for developing Cytokine Storm Syndromes, and Cytokine Storm Syndromes are being increasingly recognized around the world in pediatric and adult hospitals. A variety of infectious, rheumatic, and oncologic triggers are commonly associated with Cytokine Storm Syndromes, but understanding this disorder is critical for all researchers and physicians to ensure timely and appropriate therapy. This second edition addresses all aspects of the disorder, from genetics, pathophysiology, and ongoing research, to clinical presentations, risk factors and treatment. New-to-this-edition features include dedicated chapters on severe COVID-19 CSS, and post-COVID CSS of multi-system inflammatory syndrome in children (MIS-C). In addition, novel topics including CSS associated with Castleman disease, pregnancy, therapeutics, transplantation, and cardiac bypass, as well as treatment with JAK inhibitors are addressed. . 410 0$aAdvances in Experimental Medicine and Biology,$x2214-8019 ;$v1448 606 $aImmunology 606 $aMolecular genetics 606 $aDiseases 606 $aCytokines 606 $aImmunology 606 $aMolecular Genetics 606 $aDiseases 606 $aCytokines and Growth Factors 615 0$aImmunology. 615 0$aMolecular genetics. 615 0$aDiseases. 615 0$aCytokines. 615 14$aImmunology. 615 24$aMolecular Genetics. 615 24$aDiseases. 615 24$aCytokines and Growth Factors. 676 $a616.079 702 $aCron$b Randy Q. 702 $aBehrens$b Edward M. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910879580503321 996 $aCytokine Storm Syndrome$94206324 997 $aUNINA